Helix BioPharma Corp.

HBP

CA4229101098

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 15:58:12 2024-05-30 EDT			5-day change	1st Jan Change
0.21 ^CAD	+2.44%		0.00%	0.00%

05-14	Helix BioPharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
04-08	Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding	CI

Helix Biopharma Corp. Announces Resignation of Krzysztof Saczek from the Board of Directors

April 07, 2022 at 01:24 pm

Helix BioPharma Corp. announced the resignation of Dr. Krzysztof Saczek from the Board of Directors with immediate effect.

Latest news about Helix BioPharma Corp.

Helix BioPharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	05-13	CI
Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding	04-07	CI
Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding	03-27	CI
North American Morning Briefing : Markets Steady -2-	03-26	DJ
Helix BioPharma Corp. Appoints Praveen Varshney as Corporate Secretary	02-13	CI
Helix BioPharma Corp. Appoints Praveen Varshney as Chief Financial Officer	02-13	CI
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	12-19	DJ
Helix BioPharma Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	12-14	CI
North American Morning Briefing : Traders Eye -2-	12-12	DJ
Helix BioPharma Corp. Reports Earnings Results for the Full Year Ended July 31, 2023	23-10-27	CI
Helix BioPharma Corp. announced that it has received CAD 2.998 million in funding	23-10-26	CI
Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	23-10-10	CI
Helix Biopharma Corp. Announces Board Changes	23-08-22	CI
Helix BioPharma Corp. Announces Executive Changes	23-08-22	CI
Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in funding	23-08-14	CI
Helix BioPharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-14	CI
North American Morning Briefing : Futures Rise -2-	22-12-21	DJ
Helix BioPharma Corp. Reports Earnings Results for the First Quarter Ended October 31, 2022	22-12-14	CI
North American Morning Briefing : Investors Wary -2-	22-12-14	DJ
Helix BioPharma Corp. Announces Board Changes	22-12-08	CI
Helix BioPharma Corp. Announces CEO Changes	22-12-08	CI
Helix BioPharma Corp. Reports Earnings Results for the Full Year Ended July 31, 2022	22-10-31	CI
Helix BioPharma Corp. announced that it has received CAD 4.62902 million in funding	22-10-30	CI
Helix BioPharma Corp. Auditor Raises 'Going Concern' Doubt	22-10-30	CI
Helix BioPharma Corp. Appoints Frank Gary Renshaw as Chief Medical Officer	22-10-03	CI

Helix BioPharma Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. DOS47 is an oncology platform technology that offers a debilitation and destruction of cancer cells. DOS47 is designed to stimulate an increase in the Potential of Hydrogen (pH) of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra cellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody and is under clinical study for the treatment of non-small cell lung cancer and pancreatic cancer. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2).

Sector

Biotechnology & Medical Research

Calendar

2024-10-24 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HELIX BIOPHARMA CORP.	0.00%	35.26M
MODERNA, INC.	+43.23%	58.06B
IQVIA HOLDINGS INC.	-5.59%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+14.25%	26.7B
CELLTRION, INC.	-12.56%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-21.73%	18.98B
BIO-TECHNE CORPORATION	-0.44%	12.17B
UNITED THERAPEUTICS CORPORATION	+23.74%	12B
MEDPACE HOLDINGS, INC.	+25.08%	11.92B

Other Biotechnology & Medical Research